These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19477365)

  • 1. Atenolol is dead: long live beta-blockade.
    Cockcroft JR
    J Am Coll Cardiol; 2009 Jun; 53(22):2102; author reply 2106-7. PubMed ID: 19477365
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 3. Atenolol versus other beta-adrenergic blockers.
    Aursnes I; Osnes JB
    J Am Coll Cardiol; 2009 Jun; 53(22):2101-2; author reply 2106-7. PubMed ID: 19477363
    [No Abstract]   [Full Text] [Related]  

  • 4. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents.
    Blackburn DF; Lamb DA; Eurich DT; Johnson JA; Wilson TW; Dobson RT; Blackburn JL
    J Hypertens; 2007 Jul; 25(7):1499-505. PubMed ID: 17563574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hamon M
    Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 7. Different metabolic effects of selective and nonselective beta-blockers rather than mere heart rate reduction may be the mechanisms by which beta-blockade prevents cardiovascular events.
    Fragasso G; Cera M; Margonato A
    J Am Coll Cardiol; 2009 Jun; 53(22):2105; author reply 2106-7. PubMed ID: 19477370
    [No Abstract]   [Full Text] [Related]  

  • 8. [Criticism against the atenolol meta-analysis remains].
    Forsén K
    Lakartidningen; 2005 Feb 7-13; 102(6):412, 414; discussion 414-5. PubMed ID: 15754686
    [No Abstract]   [Full Text] [Related]  

  • 9. [Does Kent Forsen possibly have a complete picture about atenolol?].
    Carlberg B; Samuelsson O; Lindholm LH
    Lakartidningen; 2005 Jan 17-23; 102(3):151-2. PubMed ID: 15712744
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta-blockers and hypertension.
    Cruickshank JM
    J Am Coll Cardiol; 2009 Jun; 53(22):2105-6; author reply 2106-7. PubMed ID: 19477369
    [No Abstract]   [Full Text] [Related]  

  • 11. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

  • 12. [Noticeable meta-analysis of atenolol does not cover all aspects].
    Forsén K
    Lakartidningen; 2005 Jan 3-16; 102(1-2):61-3. PubMed ID: 15707110
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cardiac protection of atenolol: want of proof].
    Shi ZW
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(13):928-30. PubMed ID: 16029536
    [No Abstract]   [Full Text] [Related]  

  • 14. The LIFE Trial in 2004.
    Beevers DG
    J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
    [No Abstract]   [Full Text] [Related]  

  • 15. [The double messages about atenolol must be an issue for the SBU board].
    Werkö L; Enkvist C
    Lakartidningen; 2004 Dec; 101(49):4038, 4041; discussion 4041-2, 4045. PubMed ID: 15633347
    [No Abstract]   [Full Text] [Related]  

  • 16. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

  • 17. Beta-blocker-induced heart rate lowering, cardioprotection, and hypertension.
    Khan SS
    J Am Coll Cardiol; 2009 Jun; 53(22):2104-5; author reply 2106-7. PubMed ID: 19477368
    [No Abstract]   [Full Text] [Related]  

  • 18. [Kidney protection leads to heart protection, too].
    MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
    [No Abstract]   [Full Text] [Related]  

  • 19. Atenolol and cardiovascular risk: an issue close to the heart.
    Wilkinson IB; McEniery CM; Cockcroft JR
    Lancet; 2006 Feb; 367(9511):627-9. PubMed ID: 16503444
    [No Abstract]   [Full Text] [Related]  

  • 20. [Atenolol in treatment of patients with airway obstruction].
    Chazan R
    Pol Merkur Lekarski; 1996 Dec; 1(6):428-30. PubMed ID: 9273241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.